{"url":"https://newsforagent.com/news/2026-10-27/avalyn-pharma-warrant-lock-up-expires","markdown_url":"https://newsforagent.com/news/2026-10-27/avalyn-pharma-warrant-lock-up-expires.md","title":"Avalyn Pharma Warrant Lock-Up Ends October 27","headline":"Avalyn Pharma Warrant Lock-Up Expires October 27 After 181 Days","description":"Avalyn Pharma's warrant lock-up ends October 27, 2026, after 181 days, freeing holders from a 180-day restriction tied to its April Nasdaq listing.","section":"Regulation & Approvals","published_at":"2026-10-27T01:31:04+00:00","modified_at":"2026-10-27T01:31:04+00:00","author":"News Desk","key_takeaways":["Avalyn Pharma's warrant lock-up runs 181 days from April 29, 2026, to October 27, 2026.","Directors, executive officers and holders of substantially all outstanding stock and stock options agreed to the lock-up.","Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group L.L.C. act on behalf of the underwriters.","Avalyn completed an upsized Nasdaq IPO in April 2026, pricing 19,166,667 shares at $18.00 for $345 million in gross proceeds."],"companies":[{"name":"Avalyn Pharma","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00004ph/avalyn-pharma","website":"https://www.avalynpharma.com"},{"name":"Jefferies Financial Group","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00008l9/jefferies-financial-group","website":"https://www.jefferies.com"},{"name":"Evercore","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00027di/evercore","website":"https://www.evercore.com"}],"source":{"publisher":"MarketScreener","title":"Certain Warrants of Avalyn Pharma Inc. are subject to a Lock-Up Agreement Ending on 27-OCT-2026.","url":"https://www.marketscreener.com/news/certain-warrants-of-avalyn-pharma-inc-are-subject-to-a-lock-up-agreement-ending-on-27-oct-2026-ce785cdcd18cf123"},"other_sources":[],"tags":["Regulation & Approvals","Avalyn Pharma","Jefferies Financial Group","Evercore"],"body_markdown":"Certain warrants of [Avalyn Pharma](https://akta.pro/company-profiles/00004ph/avalyn-pharma) Inc. are subject to a lock-up agreement ending October 27, 2026, covering 181 days from April 29, 2026, [MarketScreener](https://www.marketscreener.com/news/certain-warrants-of-avalyn-pharma-inc-are-subject-to-a-lock-up-agreement-ending-on-27-oct-2026-ce785cdcd18cf123) reported. The restriction covers warrants tied to the clinical-stage biopharmaceutical company's April 2026 listing.\n\n## Avalyn's Warrant Lock-Up and Underwriter Consent\n\nUnder the agreement, directors and executive officers and the holders of substantially all of the company's outstanding stock and stock options agreed that, without the prior written consent of Morgan Stanley & Co. LLC, Jefferies LLC and [Evercore](https://akta.pro/company-profiles/00027di/evercore) Group L.L.C. on behalf of the underwriters, they will not, during the period ending 180 days after the date of the prospectus, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock. The same parties also agreed not to file any registration statement with the SEC relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of common stock.\n\n[Jefferies Financial Group](https://akta.pro/company-profiles/00008l9/jefferies-financial-group), one of the underwriters named in the agreement, kept its Boeing rating at 'Buy' with a $265 price target on October 26, 2026, citing 20 deliveries that month and FAA certification of the 737-Max-10, according to FinanzNachrichten.de.\n\n## Avalyn's IPO and Trial Enrollment\n\nAvalyn Pharma completed an upsized Nasdaq IPO in April 2026 under the ticker AVLN, pricing 19,166,667 shares, including the full over-allotment, at $18.00 per share for $345 million in aggregate gross proceeds and an implied market capitalization of about $1.1 billion, according to [akta.pro company records](https://akta.pro/company-data). The company completed target enrollment of 375 patients ahead of schedule in the Phase 2b MIST clinical trial of AP01, an inhaled pirfenidone for progressive pulmonary fibrosis, with topline 12-month data expected in the second half of 2027, the same records show.\n\n## Avalyn's Board and Conference Appearances\n\nAvalyn Pharma appointed Robert J. Meyer, MD, a former FDA senior leader, to its board of directors in September 2026, Stock Titan reported. CEO Lyn Baranowski and CFO Douglas Carlson introduced the company at Morgan Stanley's 24th Annual Global Healthcare Conference on September 14, 2026, Seeking Alpha reported. Avalyn presented new data at ERS Congress 2026 showing AP01 achieves broad lung distribution, including in severe fibrotic lungs, BioSpace reported.\n\n## Avalyn's Next Data Readout\n\nAvalyn Pharma expects topline 12-month data from the Phase 2b MIST trial of AP01 in the second half of 2027, according to akta.pro company records.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}